Clinical commissioning policy: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Document first published:: 21 October 2022
Page updated:: 11 November 2022
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Fostemsavir is recommended to be available as a routine commissioning treatment option for individuals with multi-drug resistant HIV-1 infection, when a viral suppressive regimen cannot be constructed with remaining antiretroviral agents within the criteria set out in this document.

Document

Clinical commissioning policy: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Clinical commissioning policy: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

PDF
273 KB

Document

Clinical panel report: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Clinical panel report: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

PDF
32 KB

Document

Clinical priorities advisory group summary report: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Clinical priorities advisory group summary report: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

PDF
222 KB

Document

Evidence review: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Evidence review: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

PDF
868 KB

Document

Engagement report: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Engagement report: Fostemsavir for multi-drug resistant HIV-1 infection (adult)

PDF
77 KB

Document

Equality and Health Inequalities Impact Assessment (EHIA): Fostemsavir for multi-drug resistant HIV-1 infection (adult)

Equality and Health Inequalities Impact Assessment (EHIA): Fostemsavir for multi-drug resistant HIV-1 infection (adult)

PDF
180 KB